Trump administration has postponed the launch of TrumpRx, an online portal that would let consumers purchase prescriptions directly from manufacturers at reduced prices. The move follows a letter from Senators Dick Durbin, Elizabeth Warren and Peter Welch to the HHS Office of Inspector General, demanding clarity on oversight and compliance with the anti‑kickback statute.

Lawmakers argue that similar direct‑to‑consumer sites have steered patients toward high‑cost drugs through paid telehealth partners. Their 2023 probe of Eli Lilly and Pfizer revealed up to $3 million in joint spending, with one telehealth provider prescribing the sponsor’s medication to every patient it saw. Senators also flag a possible link between TrumpRx and BlinkRx, whose board includes Donald Trump Jr.

Compliance worries could stall the platform’s revenue model, deterring investors who hoped the discount channel would capture a slice of the $350 billion U.S. prescription market. Analysts will watch for an HHS response, potential litigation under the anti‑kickback rules, and whether the administration revises the rollout to satisfy congressional oversight.